Nuvectis Pharma, Inc. Increase (Decrease) in Accounts Payable
Nuvectis Pharma, Inc. (NVCT) reported Increase (Decrease) in Accounts Payable of -$1.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-04
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $489.00K, a 75.37% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.58M, a 419.64% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$165.00K, a 169.62% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.46M, a 252.29% increase year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for fiscal 2025 was $3.78M.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$273.00K.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$139.00K, a 107.51% decline from fiscal 2022.
- Nuvectis Pharma, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.85M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $489.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$1.09M 10-Q · filed 2026-08-04 | -$1.25M derived: sum of 3 quarters · filed 2026-08-04 | $207.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$1.58M 10-Q · filed 2026-05-05 | -$1.74M derived: sum of 2 quarters · filed 2026-05-05 | -$282.00K derived: sum of 3 quarters · filed 2026-05-05 | $1.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.30M derived: sum of 2 quarters · filed 2026-02-11 | $3.28M derived: sum of 3 quarters · filed 2026-08-04 | $3.78M 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.45M derived: sum of 2 quarters · filed 2026-08-04 | $3.94M 10-Q · filed 2025-11-04 | $4.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.48M 10-Q · filed 2026-08-04 | $2.72M derived: sum of 3 quarters · filed 2026-08-04 | $3.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $494.00K 10-Q · filed 2026-05-05 | $731.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.15M derived: sum of 3 quarters · filed 2026-05-05 | $1.23M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $652.00K derived: sum of 2 quarters · filed 2026-02-11 | $739.00K derived: sum of 3 quarters · filed 2026-02-11 | -$273.00K 10-K · filed 2026-02-11 |
| 2024-09-30 | $415.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $502.00K derived: sum of 2 quarters · filed 2025-11-04 | -$510.00K 10-Q · filed 2025-11-04 | -$1.23M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$925.00K 10-Q · filed 2025-08-05 | -$1.65M derived: sum of 3 quarters · filed 2025-08-05 | $43.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$1.01M 10-Q · filed 2025-05-06 | -$1.73M derived: sum of 2 quarters · filed 2025-05-06 | -$44.00K derived: sum of 3 quarters · filed 2025-05-06 | -$337.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$721.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $968.00K derived: sum of 2 quarters · filed 2025-02-25 | $675.00K derived: sum of 3 quarters · filed 2025-02-25 | -$139.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.40M derived: sum of 2 quarters · filed 2024-11-05 | $582.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | -$293.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.11M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$814.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $1.85M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |